Simons F Estelle R
Department of Pediatrics & Child Health, University of Manitoba, Winnipeg, Canada.
J Allergy Clin Immunol. 2003 Oct;112(4 Suppl):S42-52. doi: 10.1016/s0091-6749(03)01876-1.
Histamine is an important chemical mediator of inflammation, vasodilation, increased vascular permeability, decreased peripheral resistance, airway smooth muscle contraction, and sensory nerve stimulation causing itching. It also plays a significant role in neurotransmission and in cardiac function. In allergic rhinoconjunctivitis and urticaria, there is strong evidence for the role of H(1)-antihistamine treatment. In asthma, additional dose-response studies, including higher doses of antihistamines than those used in allergic rhinitis, are needed to determine the role of antihistamines. In atopic dermatitis, the itch-relieving topical glucocorticoid-sparing effects of H(1)-antihistamines also require further documentation. The potential benefits of each H(1)-antihistamine should be weighed against the potential risks, and second-generation H(1)-antihistamines with excellent, well-documented safety records should be used in preference to older, less safe H(1)-antihistamines. Second-generation H(1)-antihistamines are more relevant than ever in the treatment of allergic disorders.
组胺是炎症、血管舒张、血管通透性增加、外周阻力降低、气道平滑肌收缩以及引起瘙痒的感觉神经刺激的重要化学介质。它在神经传递和心脏功能中也起着重要作用。在变应性鼻结膜炎和荨麻疹中,有充分证据证明H(1)抗组胺药治疗的作用。在哮喘中,需要进行额外的剂量反应研究,包括使用比变应性鼻炎中更高剂量的抗组胺药,以确定抗组胺药的作用。在特应性皮炎中,H(1)抗组胺药减轻瘙痒的局部糖皮质激素节省作用也需要进一步记录。应权衡每种H(1)抗组胺药的潜在益处与潜在风险,应优先使用安全性良好且有充分记录的第二代H(1)抗组胺药,而非安全性较低的第一代H(1)抗组胺药。第二代H(1)抗组胺药在过敏性疾病的治疗中比以往任何时候都更具相关性。